Michael J Higgins's Linkedin Analytics

Leveraging 20 years’ Senior Biotechnology Research Analyst experience to identify and drive the development of distinctive biotechnology assets. Working with my contacts and theirs to overcome hurdles in drug development. Key Contributions: - Strategic Valuation & M&A Support: Under CDA, assessed specialty pharma assets, including pipeline and approved products, for potential acquisition. Developed tailored valuation models for CDMOs, specialty pharma expansions, and as standalone entities. - Corporate Presentation & Positioning: Revised corporate presentations for previously covered companies to enhance clarity and investor appeal. Currently, I am working with an established pharma asset incubator, capitalizing on unique opportunities in today's biotech environment. My work includes: - Due Diligence & Asset Evaluation: Assessing repurposed and discarded CNS assets to determine viability and market potential. - Strategic Development & Budgeting: Identifying potential challenges in drug etiology, mapping development strategies, and refining budgets. - Market Analysis & Exit Strategies: Developing market models, "bio bucks" sale scenarios, and pinpointing potential acquirers. - Corporate Storytelling: Crafting and maintaining investor-ready presentations for both the incubator and its internal drug assets. The current biotech climate presents rare opportunities to acquire undervalued but strategically valuable drug assets. With the right positioning, these assets will attract acquirers at critical development stages in the years ahead.